Pharmacology · 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.
Сравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hoch Matthias, Hoever Petra, Zisowsky Jochen, Priestley Anthony, Fleet David, Dingemanse Jasper
Аннотация
BACKGROUND/AIMS: The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous formulation of almorexant in healthy subjects.
METHODS: A pilot phase in 3 healthy male subjects, which preceded the main study, consisted of a single 30-min intravenous infusion of 10 mg almorexant. Its objectives were to ensure the tolerability of the intravenous formulation and to select the intravenous dose for the main study. The main study was a randomized, two-way crossover study in 20 healthy subjects (10 males and 10 females). Subjects received a single oral dose of 200 mg almorexant and a single 30-min intravenous infusion of 20 mg almorexant.
RESULTS: All 23 subjects completed the study as planned. Almorexant was well tolerated; the main observed adverse events were somnolence and fatigue. A geometric mean total body clearance of 43 l/h (95% CI 39-47) and a volume of distribution of 683 liters (95% CI 552-845) were determined. The absolute oral bioavailability of almorexant was 11.2% (90% CI 9.6-13.1).
CONCLUSION: Almorexant seems to possess a pronounced first-pass effect and metabolism.
METHODS: A pilot phase in 3 healthy male subjects, which preceded the main study, consisted of a single 30-min intravenous infusion of 10 mg almorexant. Its objectives were to ensure the tolerability of the intravenous formulation and to select the intravenous dose for the main study. The main study was a randomized, two-way crossover study in 20 healthy subjects (10 males and 10 females). Subjects received a single oral dose of 200 mg almorexant and a single 30-min intravenous infusion of 20 mg almorexant.
RESULTS: All 23 subjects completed the study as planned. Almorexant was well tolerated; the main observed adverse events were somnolence and fatigue. A geometric mean total body clearance of 43 l/h (95% CI 39-47) and a volume of distribution of 683 liters (95% CI 552-845) were determined. The absolute oral bioavailability of almorexant was 11.2% (90% CI 9.6-13.1).
CONCLUSION: Almorexant seems to possess a pronounced first-pass effect and metabolism.